Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

• Alexander P. Bye,
• Neline Kriek,
• Tanya Sage,
• Suzannah J. Rawlings,
• Catherine Prodger,
• Murali Kesavan,
• Charlotte Lees,
• Stephen Booth,
• Louise G. Cowen,
• Kirsty Shefferd,
• Michael J. Desborough,
• Jonathan M. Gibbins,
• Toby A. Eyre

Affiliations

Alexander P. Bye

Molecular and Clinical Sciences Research Institute, St George's University, Cranmer Terrace, London, United Kingdom; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX

Neline Kriek

Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX

Tanya Sage

Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX

Suzannah J. Rawlings

Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading,

Catherine Prodger

Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE

Murali Kesavan

Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE

Charlotte Lees

Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE

Stephen Booth

Department of Clinical Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, RG1 5AN

Louise G. Cowen

Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE

Kirsty Shefferd

Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE

Michael J. Desborough

Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE

Jonathan M. Gibbins

Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX

Toby A. Eyre

Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,